Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05097326 · ClinicalTrials.gov registry record · Phase 3
Mifepristone for Labor Induction
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT05097326: Completed Phase 3 study, sponsored by Stanford University.
NCT05097326 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05097326, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to explore mifepristone as an option for induction of labor at term by evaluating the efficacy of mifepristone use for cervical preparation. Since the Labor Induction versus Expectant Management in Low-Risk Nulliparous Women (ARRIVE) trial supporting that elective induction after 39 weeks decreases cesarean sections and morbidity, rates of elective term inductions are increasing. At Lucile Packard Children's Hospital at Stanford University specifically, approximately 40% of spontaneous vaginal deliveries follow induction of labor, with an average induction time of 20 hours. Previous studies have established the maternal and neonatal safety of mifepristone in term inductions, however, this study will assess the difference in overall time from induction to complete cervical dilation, delivery, and the total time on Labor and Delivery.
Interventions
- DRUG Mifepristone
- DRUG Misoprostol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2023-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05097326
The ClinicalTrials.gov registry entry for NCT05097326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mifepristone is the first listed.
NCT05097326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05097326 about?
NCT05097326 is a clinical study titled "Mifepristone for Labor Induction". The purpose of this trial is to explore mifepristone as an option for induction of labor at term by evaluating the efficacy of mifepristone use for cervical preparation. Since the Labor Induction versus Expectant Management in Low-Risk Nulliparous Women (ARRIVE) trial supporting that elective induct...
What is the current status of trial NCT05097326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2022-06-27. Estimated completion is 2023-04-29.
What interventions are being tested in trial NCT05097326?
The interventions under investigation include: Mifepristone (DRUG), Misoprostol (DRUG).
Who is sponsoring clinical trial NCT05097326?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.